Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
News|Articles|March 26, 2019
- Pharmaceutical Technology\'s In the Lab eNewsletter-04-03-2019
- Volume 14
- Issue 4
Dual Impeller Single-Use Bioreactor
Author(s)Pharmaceutical Technology Editors
Distek, a provider of laboratory testing instruments, added a dual impeller single-use bioreactor (SUB) system to its BIOne portfolio.
Distek, a manufacturer of laboratory testing instruments for the pharmaceutical and biotechnology industry, has added a dual impeller single-use bioreactor (SUB) system to its BIOne portfolio.
The new SUB increases mixing efficiency within the bioreactor, resulting in an increased mass transfer coefficient (kLa) while maintaining the same rate of agitation.
“Optimized mammalian processes are yielding higher cell densities and more product than ever,” said Cristy Botens, product manager of Bioprocessing, Distek, in a March 21, 2019 company press release. “We’ve developed a dual impeller SUB configuration to improve mixing efficiency and provide higher kLa values to support our customers as they develop tomorrow’s medicines and cures.”
Source:
Articles in this issue
over 7 years ago
Ensuring Robust Stability Testing for Product Longevityover 7 years ago
Lonza Strengthens Cell Capabilitiesover 7 years ago
Clinical Water Purification System Gets Digital Updateover 7 years ago
Lilly and ImmuNext Announce Licensing and Research Collaborationover 7 years ago
Tosoh Bioscience Introduces New MALS Detector at Pittcon 2019over 7 years ago
New Protein Characterization Technique Unveiled at Pittcon 2019Related to this article
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech AI Pulse Check: AI Watermark Vulnerability
5